Cardano and Solana may hit fresh ATHs, but analysts see Layer Brett’s $2M+ presale at $0.0053 as the real 5,000% moonshot for 2025 gains.Cardano and Solana may hit fresh ATHs, but analysts see Layer Brett’s $2M+ presale at $0.0053 as the real 5,000% moonshot for 2025 gains.

Layer Brett Set For 5,000% Boom Before Cardano And Solana Smash Fresh All-Time Highs

cardano64587 image 40

The crypto market is buzzing again, with analysts eyeing fresh highs for Cardano (ADA) and Solana (SOL) as liquidity pours back into majors. Yet, while both chains could grind toward new all-time highs in 2025, the reality is simple: the upside is capped. ADA and SOL are already “institutionalized bags.” 

By contrast, Layer Brett ($LBRETT) has exploded in presale hype, blasting past $2 million in funding with tokens still priced at just $0.0053. For investors chasing asymmetric gains, Brett isn’t just another meme coin. It’s an Ethereum Layer 2 narrative play wrapped in meme virality, set to move 5,000% before the blue chips crawl to new peaks. Here’s why.

image 1 37

Cardano: The ivory tower dilemma is real

Cardano has spent years building an academic-first approach to blockchain — praised by some, but mocked by many as “slow-motion crypto.” Its smart contract rollouts have lagged, its dApp ecosystem underwhelms, and liquidity continues bleeding to faster, cheaper chains. Yes, ADA bulls point to $5 price targets in the next cycle, but even that requires billions in fresh inflows. A 2x or 3x at this stage isn’t worth the opportunity cost when new players like Layer Brett are delivering meme-level virality plus Ethereum-native infrastructure. ADA may hit new highs, but it’s offering peanuts compared to Brett’s parabolic potential.

Solana: No longer the moonbag it once was

Solana has become Ethereum’s top competitor, thriving on high throughput and cheap fees. The Solana meme coin boom, from BONK to Dogwifhat, injected massive cultural capital into its ecosystem. Yet FUD remains sticky: outages, governance opacity, and the fact that institutional trust still flows to Ethereum first. Solana is a blue chip now, not a moonbag. That leaves retail chasing safer 2–5x plays, while the degen capital seeks out low caps like Layer Brett that can still 100x on pure momentum.

Layer Brett: The Ethereum L2 meme with teeth

What makes Layer Brett stand apart is its dual identity: meme energy fused with Ethereum Layer 2 crypto infrastructure. Transactions are fast, fees are pennies, and the ecosystem is scalable by design. It’s not just a token; it’s a plug-in growth engine for the Ethereum network — the same chain forecast to process trillions annually by 2027.

The presale numbers tell the story: more than $2 million raised, with early entry locked in at $0.0053. Staking rewards in the tens of thousands of percent for early adopters add fuel to the fire. And unlike legacy memes like SHIB or PEPE or big caps like ADA and SOL, which are stagnating at billion-dollar caps, Layer Brett is a fresh entry primed to capture both retail FOMO and Ethereum-driven institutional inflows.

image 1 54

$LBRETT primed to go on a 5,000% run in 2025

Cardano and Solana will remain staples of the altcoin landscape, and both could chart new highs in the coming cycle. But they’re no longer the best hunting ground for exponential wealth creation. That spotlight now belongs to Layer Brett. 

The ROI profile is clear as crystal. ADA and SOL may mint fresh ATHs in the future—but only after absorbing tens of billions in liquidity. Layer Brett doesn’t need that. A fraction of inflows into Ethereum ecosystem plays could send Brett on a 5,000% run before majors even blink.

LBRETT is available now at $0.0053. Don’t miss out on the next 100x—join the Layer Brett presale today.

Website: https://layerbrett.com

Telegram: https://t.me/layerbrett

X: Layer Brett (@LayerBrett) / X

This article is not intended as financial advice. Educational purposes only.

Market Opportunity
RealLink Logo
RealLink Price(REAL)
$0.07913
$0.07913$0.07913
-1.76%
USD
RealLink (REAL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26